Cder phase II biosimilars order
Ended Awarded Last action
- Contract number
- 75F40119F80339
- Awardee
-
Palladian Partners, Inc. UEI SJGQXJEFBKC5 Part of Altarum Institute
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $901,744
Award facts
- Contract value 100% obligated
- $901,743.54 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541820 Public Relations Agencies
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$132,239 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $89,515 | |
| Exercise an Option | $309,943 | |
| Exercise an Option | $310,727 | |
| Other Administrative Action | $0 | |
| Original award | $323,798 |
About this award
This is a delivery order awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Palladian Partners, Inc., a for-profit company that specializes in health and science communications. The contract has a potential value of $901,743.54 and was issued under the General Services Administration's (GSA) Professional Services Schedule (PSS). It does not have a set-aside designation.
Palladian Partners, a subsidiary of the nonprofit Altarum Institute, has been awarded over $130 million in federal contracts from agencies like HHS, the National Institutes of Health (NIH), FDA, and Centers for Disease Control and Prevention (CDC) to provide strategic marketing, public relations, meeting planning, program support, and outreach services. This specific order is for the FDA's Center for Drug Evaluation and Research (CDER) Phase II Biosimilars program, which supports the development and approval of biosimilar drug products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved biological product.
Quick answers
Who was awarded contract 75F40119F80339?
75F40119F80339 was awarded to Palladian Partners, Inc. by Food and Drug Administration (Department of Health and Human Services) on August 26, 2019.
How much is contract 75F40119F80339 worth?
The government has obligated $901,744 on 75F40119F80339.
Is contract 75F40119F80339 an order under another contract?
Yes. 75F40119F80339 is a delivery order under GS23F0270L, a federal supply schedule, on The Professional Services Schedule (PSS).
Was contract 75F40119F80339 competed?
The extent of competition for 75F40119F80339 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award